15 recruiting, 8 not yet recruiting, 2 active not recruiting, 2 enrolling by invitation. 20 Phase 2, 10 Phase 1, 6 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Azacitidine (AZA): new trials by email Literature Review of Azacitidine (AZA) trials Research Report on Azacitidine (AZA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations ropeginterferon alfa- 2b, Azacitidine (AZA) - Ropeginterferon, Alfa-2b | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-10-27 | 2026-10-16 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Olutasidenib, Azacitidine (AZA) - IDH1 Mutation, Relapsed / Refractory AML | Phase 2 | Recruiting | Timothy Pardee | 25 | 2026-09-01 | 2026-09-02 |
| A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia Azacitidine (AZA), Venetoclax, Allogeneic hematopoietic stem cell transplantation - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-08-04 | 2026-08-05 | |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. Azacitidine (AZA) - Peripheral T-Cell Lymphoma Refractory | Early Phase 1 | Recruiting | Second Affiliated Hospital of Soochow University | 30 | 2026-06-01 | 2026-05-20 |
| VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML Venetoclax (VEN), Azacitidine (AZA), Allo-HSCT - Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 50 | 2026-06-01 | 2026-06-09 |
| Study of SA+X in the Treatment of Newly Diagnosed AML Anthracycline, Ivosidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ruijin Hospital | 205 | 2026-05-01 | 2026-07-30 |
| A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 52 | 2026-05-01 | 2026-05-07 |
| Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days - Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 112 | 2026-04-09 | 2026-10-08 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax Venetoclax, Azacitidine (AZA) - Acute Myeloid Leukemia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 250 | 2026-02-01 | 2026-02-12 |
| Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL Zeprumetostat, Azacitidine (AZA), Mitoxantrone Hydrochloride Liposome - Peripheral T Cells Lymphoma (PTCL) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2026-01-15 | 2026-01-28 |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Ziftomenib, Placebo, Venetoclax - Acute Myeloid Leukemia (AML) | Phase 3 | Recruiting | Kura Oncology, Inc. | 1300 | 2025-09-26 | 2026-10-13 |
| Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients VEN (Venetoclax), Azacitidine (AZA), Chidamide - Adult T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 27 | 2025-09-01 | 2026-10-16 |
| Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML Venetoclax, Azacitidine (AZA), Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 50 | 2025-06-20 | 2026-10-13 |
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Enrolling by invitation | Andrew P. Groves | 34 | 2025-06-05 | 2025-06-26 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myeloid, Acute (20) · Myelodysplastic Syndromes (6) · Leukemia (5) · Neoplasm, Residual (4) · Hematologic Neoplasms (2) · Recurrence (2) · Astrocytoma (1) · Glioblastoma (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Philadelphia Chromosome (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
The First Affiliated Hospital of Soochow University (5) · Janssen Research & Development, LLC (2) · M.D. Anderson Cancer Center (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Andrew P. Groves (1) · Beijing 302 Hospital (1) · Ellipses Pharma (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (1) · Guangdong Second Provincial General Hospital (1) · Jacqueline Garcia, MD (1) · Kura Oncology, Inc. (1) · Maxinovel Pty., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Peking Union Medical College Hospital (1)
China (14) · United States (11) · United Kingdom (6) · Canada (5) · Spain (5) · Australia (4) · France (4) · Germany (4) · Italy (4) · Belgium (3) · South Korea (3) · Taiwan (3) · Czechia (2) · Greece (2) · Hungary (2)
Bingzong Li, Professor (1) · Bo Cai, MD (1) · Christoph Rummelt, MD, PhD (1) · David Taussig (1) · Guopan Yu, PhD (1) · Jacqueline Garcia, MD (1) · Jayastu Senapati, MD (1) · Jordi Esteve, M.D.; Ph.D. (1) · Jorge Cortes, MD (1) · Qian Jiang, Dr. (1) · Roni Tamari, MD (1) · Shilpan Shah, MD (1) · Suning Chen (1)
2023 (1), 2025 (1)